Valuing a Cure: Evaluating Different Approaches to Determine a Value-Based Price for a Potential Cure
Steven D. Pearson, Institute for Clinical and Economic Review
Many drugs in the development pipeline offer the potential to cure patients but will almost certainly enter the market with very high price tags. This study will extend ICER's current value assessment framework to tackle difficult conceptual and methodological issues related to establishing fair, value-based initial prices for these drugs. The work will be applied to a real-world case study of an emerging potential cure and incorporated into an update of ICER's value assessment framework. Findings will also be shared with international technology assessment organizations.